Gefitinib resistance resulted from STAT3-mediated Akt activation in lung cancer cells

被引：57

作者：

Wu, Kai ^{[1
]}

Chang, Qingshan ^{[1
]}

Lu, Yongju ^{[1
]}

Qiu, Ping ^{[1
]}

Chen, Bailing ^{[1
]}

Thakur, Chitra ^{[1
]}

Sun, Jiaying ^{[1
]}

Li, Lingzhi ^{[1
]}

Kowluru, Anjaneyulu ^{[1
]}

Chen, Fei ^{[1
]}

机构：

[1] Wayne State Univ, Dept Pharmaceut Sci, Eugene Applebaum Coll Pharm & Hlth Sci, Detroit, MI 48202 USA

来源：

ONCOTARGET | 2013年 / 4卷 / 12期

关键词：

Gefitinib; EGFR; STAT3; Akt recovery; GROWTH-FACTOR RECEPTOR; SIGNALING PATHWAYS; EGFR INHIBITORS; STAT3; PHOSPHORYLATION; ONCOGENIC RESISTANCE; TUMOR-GROWTH; IN-VIVO; CONTRIBUTES; MUTATIONS; PI3K/AKT;

D O I：

10.18632/oncotarget.1431

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Hyperactivation of Epidermal Growth Factor Receptor (EGFR) tyrosine kinase is prevalent in human lung cancer and its inhibition by the tyrosine kinase inhibitors (TKIs), including gefitinib and erlotinib, initially controls tumor growth. However, most patients ultimately relapse due to the development of drug resistance. In this study, we have discovered a STAT3-dependent Akt activation that impairs the efficacy of gefitinib. Mechanistically, gefitinib increased association of EGFR with STAT3, which de-repressed STAT3 from SOCS3, an upstream suppressor of STAT3. Such a de-repression of STAT3 in turn fostered Akt activation. Genetic or pharmacological inhibition of STAT3 abrogated Akt activation and combined gefitinib with STAT3 inhibition synergistically reduced the growth of the tumor cells. Taken together, this study suggests that activation of STAT3 is an intrinsic mechanism of drug resistance in response to EGFR TKIs. Combinational targeting on both EGFR and STAT3 may enhance the efficacy of gefitinib or other EGFR TKIs in lung cancer.

引用

页码：2430 / 2438

页数：9

共 41 条

[1] Signal Transducer and Activator of Transcription-3, Inflammation, and Cancer How Intimate Is the Relationship? [J].